Enhance tumor response,
reduce side effects.
Every year, 1.8 million patients1 receive radiation meant to kill their cancer — yet treatment is often limited by damage to the healthy tissue around it. BMX-001 is designed to change the equation: enhancing tumor response to radiation and chemotherapy while reducing side effects.
BMX-001 is an investigational product. BioMimetix has no product approved by the FDA or any other regulatory authority. View full disclaimers.
Validated with clinical evidence.
Regulatory recognition.
* Breakthrough Therapy, Fast Track, and Orphan Drug designations all apply to the glioma indication only.
Go deeper into BioMimetix.
The full clinical, commercial, and strategic story — organized section by section.
Behind every data point, a patient.
BMX-001 is measured not only in early clinical data, but in the potential for patients to better tolerate treatment, maintain full dosing, and live longer.
One mechanism.
Every solid tumor.
BMX-001 does not target a single cancer. It modulates the redox biology that radiation itself exploits — sensitizing tumors while protecting the normal tissue radiation harms. Because roughly 90% of cancers are solid tumors1 and about half of all cancer patients receive radiation therapy10, that mechanism has the potential to reach across nearly the entire solid-tumor landscape.
Sensitizes Tumors
Inhibits HIF-1α to weaken tumor defenses against radiation — a mechanism shared by virtually all irradiated solid tumors, not one histology.
Protects Normal Tissue
Inhibits NF-κB to shield healthy tissue from radiation injury — potentially widening the therapeutic window wherever radiation is used.
Indication-Agnostic by Design
Because the mechanism is tied to radiation biology rather than a specific cancer type, the platform has potential applicability across the solid-tumor landscape.
Broad applicability is a potential based on mechanism and the central role of radiation in solid-tumor care; it must be confirmed in clinical studies for each individual indication.
The neurology pipeline.
A platform built for the brain.
BMX-001's redox-active mechanism is a natural fit for neuro-oncology — with the potential to enhance tumor kill while protecting cognition and white matter that radiation threatens. Clinical findings in glioma support this; the pipeline ahead extends it4.
Brain Metastases
Whole-brain radiation neuroprotection — preserving cognition in the ~200K U.S. patients treated annually.
Pediatric CNS Tumors
Reducing long-term neurocognitive injury in children receiving cranial radiation — where late effects matter most.
Radiation Neuroprotection
Shielding healthy brain tissue from radiation-induced cognitive decline — a major unmet need with no approved therapy.
Next-Gen MnP Compounds
BMX-201 / BMX-202 designed with the goal of improved CNS penetration and tuned redox activity.
Beyond the Current Pipeline
Beyond its current oncology programs, BioMimetix sees potential to apply its redox platform to CNS and other diseases driven by oxidative stress and inflammation.56789
A Natural Fit for the Brain
The brain is particularly vulnerable to oxidative stress. BMX-001's SOD-mimetic redox activity targets reactive oxygen species and downstream inflammatory signaling — mechanisms relevant to both treatment-related CNS injury and broader neurologic disease.
Indication-Agnostic Scaffold
The redox-active manganese porphyrin platform is tunable — extendable to neuroinflammation, ischemia-reperfusion, and other oxidative-stress-driven pathologies beyond oncology.
Regulatory Experience
FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations in high-grade glioma provide BioMimetix with regulatory experience that can inform development of BMX-001 and future candidates in additional CNS indications.
Developed through leading academic and cooperative-group collaborations
BMX-001 has advanced through collaborations with leading academic medical centers, NCI-supported research programs, and national cooperative trial groups — from early development and federal research funding to multi-institutional clinical trials11.
Major Universities & Academic Medical Centers
Founders, KOLs, and trial sites drawn from the nation's leading research institutions.
NIH / NCI11
Peer-reviewed federal grant funding supports the platform, including the NCI-funded expansion of BMX-001 into colorectal carcinoma.